An Economic Evaluation of Risankizumab vs. Adalimumab in Moderate to Severe Plaque Psoriasis Adult Patients in Egypt
Author(s)
Saher M. Elmously, BSc, PharmD1, Areej H. Amer, MSC's candidate pharmacology and Toxicology2, Nour Walid, BSc in Clinical Pharmacy -Misr International Uni3, Mahmoud T. Gaber, BSc MUST University4, Mohamed Hassan, BSc Pharmacy Helwan University5, Rania Elhusseiny, Associate Prof of Dermatology6, Dina Saadi, Associate Prof of Dermatology7, Gihan Hamdy Elsisi, Sr., BSc, MSc, PhD8.
1Market Access, Abbott, Riyadh, Saudi Arabia, 2MOHAP, Cairo, Egypt, 3World health organization (WHO), Cairo, Egypt, 4Astellas, Dubai, United Arab Emirates, 5Jhonson & Jhonson, Cairo, Egypt, 6Ain Shams University, Cairo, Egypt, 7Cairo University, Cairo, Egypt, 8The American University in Cairo, cairo, Egypt.
1Market Access, Abbott, Riyadh, Saudi Arabia, 2MOHAP, Cairo, Egypt, 3World health organization (WHO), Cairo, Egypt, 4Astellas, Dubai, United Arab Emirates, 5Jhonson & Jhonson, Cairo, Egypt, 6Ain Shams University, Cairo, Egypt, 7Cairo University, Cairo, Egypt, 8The American University in Cairo, cairo, Egypt.
OBJECTIVES: Plaque psoriasis (PsO) is a common, chronic autoimmune disease. Patients mainly suffer from pain, sleep interference, difficulty concentrating, dry, itchy, raised skin patches (plaques) covered with scales that appear on the elbows, knees, lower back, and scalp. The patches vary in color, depending on skin color. Several clinical trials have shown that patients who used Risankizumab achieved 90% clearer skin compared to Adalimumab. Our main objective is to assess the costs and outcomes of Risankizumab and Adalimumab for treating moderate to severe PsO in adult patients in Egypt over a 1-year time horizon.
METHODS: A Markov cohort model was constructed from the payer's perspective to assess Risankizumab versus Adalimumab in treating PsO for 16 weeks and assessed based on Psoriasis Area and Severity Index (PASI) scores. Successful responders who scored a minimum PASI score of 75 transitioned to a maintenance phase, while those who scored PASI (50-74) considered as primary nonresponsive and received Ustekinumab as the preferred supportive care and not received systemic oral treatments, validated with the local dermatology physicians. The cost of medications was captured from the unified procurement authority in Egypt while the cost of services captured from the governmental hospitals. All costs were converted to USD for comparability of results. One-way sensitivity analyses were performed.
RESULTS: The cumulative cost of Risankizumab and Adalimumab over 1 year was $38,626 and $13,147, respectively, resulting in an incremental cost-effectiveness ratio (ICER) of $4,311,314. This means that Risankizumab is not cost-effective, as the country's willingness-to-pay threshold is $58,758.
CONCLUSIONS: Risankizumab was found to be not cost-effective compared to Adalimumab for treating moderate to severe PsO in Egypt. The ICER of Risankizumab significantly exceeds the acceptable threshold, indicating that the additional cost of the drug outweighs its minimal improvement in patient outcomes.
METHODS: A Markov cohort model was constructed from the payer's perspective to assess Risankizumab versus Adalimumab in treating PsO for 16 weeks and assessed based on Psoriasis Area and Severity Index (PASI) scores. Successful responders who scored a minimum PASI score of 75 transitioned to a maintenance phase, while those who scored PASI (50-74) considered as primary nonresponsive and received Ustekinumab as the preferred supportive care and not received systemic oral treatments, validated with the local dermatology physicians. The cost of medications was captured from the unified procurement authority in Egypt while the cost of services captured from the governmental hospitals. All costs were converted to USD for comparability of results. One-way sensitivity analyses were performed.
RESULTS: The cumulative cost of Risankizumab and Adalimumab over 1 year was $38,626 and $13,147, respectively, resulting in an incremental cost-effectiveness ratio (ICER) of $4,311,314. This means that Risankizumab is not cost-effective, as the country's willingness-to-pay threshold is $58,758.
CONCLUSIONS: Risankizumab was found to be not cost-effective compared to Adalimumab for treating moderate to severe PsO in Egypt. The ICER of Risankizumab significantly exceeds the acceptable threshold, indicating that the additional cost of the drug outweighs its minimal improvement in patient outcomes.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE46
Topic
Economic Evaluation
Disease
Biologics & Biosimilars, Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)